XCSport体育
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
XCSport体育:Products in R&D
Clinical Trial
Science & Technology
R&D Result
XCSport体育:Innovation Centre
XCSport体育:Technology Platform
Quality Management
Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Corporate Governance
XCSport体育:Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
XCSport体育:Multi-media
XCSport体育:Media Reports
XCSport体育:Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
XCSport体育:Customer Message
Privacy
XCSport体育:Legal Statement
XCSport体育:Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
XCSport体育:Company Profile
Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
XCSport体育:Clinical Trial
XCSport体育:Science & Technology
R&D Result
XCSport体育:Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
XCSport体育:Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
XCSport体育:Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
XCSport体育:Customer Message
Privacy
Legal Statement
XCSport体育:Compliance
搜索
Be the most trusted biotech company
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2025-05-16
Henlius to Showcase at BIO 2024
2025-05-15
First Patient Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab
2025-05-14
Henlius lasofoxifene HLX78 IND Approved by NMPA
2025-05-10
Henlius Holds its first Scientific Advisory Board Meeting of 2024
2025-05-06
Henlius Dual HER2 Blockade Therapy Receives Phase 3 MRCT IND Approval from U.S. FDA
2025-04-29
Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products
2025-04-26
Henlius Trastuzumab Receives FDA Approval in the United States
2025-04-25
Henlius to Showcase Latest Results of Serplulimab at 2024 ASCO
2025-04-23
First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Novel Anti-GARP/TGF-β1 mAb HLX6018
1
...
4
5
6
7
8
9
10